These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31741199)

  • 1. RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design.
    Xia AD; Schaefer CP; Szende A; Jahn E; Hirst MJ
    Drugs Real World Outcomes; 2019 Dec; 6(4):193-203. PubMed ID: 31741199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
    Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.
    Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G
    Ther Innov Regul Sci; 2024 Nov; 58(6):1042-1052. PubMed ID: 39060838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
    Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
    Deverka PA; Douglas MP; Phillips KA
    Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies.
    Burns L; Kalesnik-Orszulak R; Spring R; Zeegers F; Rutstein M; Hukkelhoven M; Wruck L; O'Donnell J
    Adv Ther; 2022 Oct; 39(10):4772-4778. PubMed ID: 35972721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward a better understanding about real-world evidence.
    Liu M; Qi Y; Wang W; Sun X
    Eur J Hosp Pharm; 2022 Jan; 29(1):8-11. PubMed ID: 34857642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.
    Burns L; Roux NL; Kalesnik-Orszulak R; Christian J; Hukkelhoven M; Rockhold F; O'Donnell J
    Clin Ther; 2022 Mar; 44(3):420-437. PubMed ID: 35181179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paving the way for patient centricity in real-world evidence (RWE): Qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation.
    Maruszczyk K; McMullan C; Aiyegbusi OL; Keeley T; Wilson R; Collis P; Bottomley C; Calvert MJ
    Heliyon; 2023 Sep; 9(9):e20157. PubMed ID: 37809473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies.
    Radawski CA; Hammad TA; Colilla S; Coplan P; Hornbuckle K; Freeman E; Smith MY; Sobel RE; Bahri P; Arias AE; Bennett D
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1532-1539. PubMed ID: 33146901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.
    Jaksa A; Wu J; Jónsson P; Eichler HG; Vititoe S; Gatto NM
    J Comp Eff Res; 2021 Jun; 10(9):711-731. PubMed ID: 33928789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Healthcare Claims Data to Generate Real-World Evidence on Patients With Drug-Resistant Epilepsy: Practical Considerations for Research.
    Stamas N; Vincent T; Evans K; Li Q; Danielson V; Lassagne R; Berger A
    J Health Econ Outcomes Res; 2024; 11(1):57-66. PubMed ID: 38425708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.